European Commission Approves New Treatment for Severe Asthma

Calabria News

Giornale Radio

View article

Reposted by

Giornale Radio

Factuality

Ownership

In severe asthma, biological therapy with mepolizumab "consists a change in the history of the disease, because we go to act on the epithelium and remodelling. By blocking interleukin 5 we go to block both the upstream mechanisms upstream, "until we reach the epithelium, and all the downstream mechanisms" and then downstream, "retarding basically the migration of eosinophils and [...] L'articolo Farmaci, Scioscia (UniFg): "With mepolizumab carri…

Quotidiano Nazionale

notizie.it

View article

Reposted by

notizie.it

Factuality

Ownership

With mepolizumab we have clinical efficacy data not only at 12 months but also longitudinal data, with the Bagnasco study, up to 3 years. Early intercepting patients with a T2 phenotype and with features such as mucus caps or small airway impairment allows to achieve an efficacy result as early as 12 months of treatment and to maintain clinical remission up to 3 years.

Rec News | Lontani dal mainstream

Factuality

Ownership

Depemoximab will be a revolution in the revolution of biological therapy for severe asthma, because for the patient there is an infinite benefit and not only in everyday life, thanks to the fact that you don't have to worry about including the administration of the therapy in your daily journey. Let's not forget that these are often young patients who continue to work and [...] L'articolo Health, Crimes (UniCt): "ultra-long-acting a revolution f…

canaledieci.it

Factuality

Ownership

The first ultra-long-acting biological drug for the treatment of severe asthma, depemokimab, offers an extra opportunity and changes the treatment paradigm. In fact, we have important results on the efficacy of therapy, as shown by Swift studies, which confirm the ability to inhibit inflammation by acting on interleukin 5 (Il-5). In addition, it gives us the opportunity to intervene [...]